Which peptides have been studied in growth hormone research?
-
AOD-9604hGH Fragment 176-191
Growth hormone fragment studied for weight management. Not licensed in the UK; its largest human trial showed no significant weight-loss benefit.
ModerateNot licensed in the UK -
CJC-1295CJC-1295 with DAC
Long-acting growth-hormone-releasing hormone analogue studied for hormone levels in healthy adults. Not licensed in the UK; human evidence is small, short trials.
LimitedNot licensed in the UK -
GHRP-2Pralmorelin
Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK; Japan licenses it only as a diagnostic test. No trial shows a health benefit.
LimitedNot licensed in the UK -
GHRP-6Growth hormone-releasing…
Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK. Human studies are short hormone-response and diagnostic work; no trial shows a health benefit.
LimitedNot licensed in the UK -
HexarelinExamorelin
Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK. In a long-term human study the response faded and IGF-I and body composition did not change.
LimitedNot licensed in the UK -
IpamorelinIPA
Synthetic growth hormone secretagogue studied for growth hormone release. Not licensed in the UK; human evidence is one small pharmacokinetic study.
LimitedNot licensed in the UK -
SermorelinSermorelin acetate
Synthetic growth-hormone-releasing hormone fragment studied in children with growth hormone deficiency. Not licensed in the UK; evidence is mainly from before 2000.
LimitedNot licensed in the UK -
TesamorelinTH9507
Not licensed in the UK. Growth-hormone-releasing hormone analogue studied for visceral fat in HIV-associated lipodystrophy, in randomised trials.
StrongNot licensed in the UK
Best recorded finding for each peptide in this area
| Peptide | UK status | Finding | Study type | Evidence grade |
|---|---|---|---|---|
| CJC-1295 | Not licensed in the UK | Growth hormone and IGF-1 elevation | Human trial | Limited |
| GHRP-2 | Not licensed in the UK | Adult GH deficiency test, Japan | Human trial | Limited |
| GHRP-6 | Not licensed in the UK | Phase I pharmacokinetics, nine men | Human trial | Limited |
| Hexarelin | Not licensed in the UK | Amount-dependent GH, cortisol, prolactin | Human trial | Limited |
| Ipamorelin | Not licensed in the UK | Healthy male pharmacokinetic study | Human trial | Limited |
| Sermorelin | Not licensed in the UK | 1999 review, childhood GH deficiency | — | Limited |
About this research area
"Growth Hormone Research" covers peptides studied for their action on the growth-hormone-releasing hormone (GHRH) receptor or the ghrelin/GH-secretagogue receptor pathway, and their downstream effect on pituitary growth hormone release and circulating IGF-1. Research in this area includes human dose-escalation pharmacokinetic studies, diagnostic-use trials in paediatric growth-hormone deficiency, and body-composition trials in specific clinical populations. Peptides in this category differ considerably in the strength, age and regulatory history of their supporting evidence; inclusion reflects a shared mechanism of research interest, not equivalent evidence quality across peptides.
27 sources in the library relate to this area. See them.
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.